|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,702,725: Olanzapine Compositions
U.S. Patent 5,702,725, titled "Olanzapine Compositions," issued on December 30, 1997, to Eli Lilly and Company. The patent claims novel formulations of olanzapine, an atypical antipsychotic, designed to improve its stability and dissolution properties. These formulations are primarily directed at oral dosage forms, aiming to enhance patient compliance and therapeutic efficacy.
What are the core claims of U.S. Patent 5,702,725?
The patent's primary claims focus on specific pharmaceutical compositions containing olanzapine.
-
Claim 1 describes a solid pharmaceutical composition comprising:
- Olanzapine.
- A binder.
- A disintegrant.
- A lubricant.
- At least one pharmaceutically acceptable excipient selected from the group consisting of diluents and glidants.
- The composition is characterized by a specific dissolution profile. Specifically, when tested in a USP apparatus 2 (paddle) at 50 rpm in 900 mL of 0.05 M phosphate buffer at pH 6.8 and 37°C, at least 75% of the olanzapine dissolves within 30 minutes.
-
Claim 2 is dependent on Claim 1, further specifying that the diluent is lactose.
-
Claim 3 is dependent on Claim 1, further specifying that the binder is hydroxypropyl cellulose.
-
Claim 4 is dependent on Claim 1, further specifying that the disintegrant is sodium starch glycolate.
-
Claim 5 is dependent on Claim 1, further specifying that the lubricant is magnesium stearate.
-
Claim 6 describes a solid pharmaceutical composition comprising:
- Olanzapine.
- Lactose.
- Hydroxypropyl cellulose.
- Sodium starch glycolate.
- Magnesium stearate.
- This composition also meets the dissolution requirement specified in Claim 1.
-
Claim 7 claims a method of treating a psychotic disorder by administering a dosage unit of the composition defined in Claim 1.
-
Claim 8 claims a method of treating a psychotic disorder by administering a dosage unit of the composition defined in Claim 6.
-
Claim 9 is a process claim, detailing a method for preparing a solid pharmaceutical composition comprising:
- Blending olanzapine with lactose, hydroxypropyl cellulose, and sodium starch glycolate.
- Granulating the blend.
- Drying the granules.
- Lubricating the dried granules with magnesium stearate.
- Compressing the lubricated granules into tablets.
-
Claim 10 claims a solid pharmaceutical composition prepared by the method of Claim 9.
The patent's inventive step lies in identifying a specific combination of excipients and processing conditions that yield olanzapine compositions with improved, predictable dissolution rates, which are crucial for bioavailability and therapeutic effect.
What is the significance of the dissolution profile claimed in the patent?
The specified dissolution rate, where at least 75% of olanzapine dissolves within 30 minutes under defined USP apparatus 2 conditions, is critical for several reasons:
-
Bioavailability: Faster and more consistent dissolution generally leads to more predictable and complete absorption of the drug in the gastrointestinal tract. This ensures that a therapeutic concentration of olanzapine is reached in the bloodstream, enhancing its efficacy in treating psychotic disorders [1].
-
Therapeutic Equivalence: For generic drug manufacturers, meeting this specific dissolution profile is a key criterion for demonstrating bioequivalence to the reference listed drug (RLD), which in turn is necessary for U.S. Food and Drug Administration (FDA) approval. This patent thus defines a benchmark for generic formulations.
-
Stability: While not explicitly a stability patent, improved dissolution can often be correlated with more stable formulations. The selection of specific excipients and their interaction with the active pharmaceutical ingredient (API) can prevent degradation pathways.
-
Manufacturing Reproducibility: The claimed compositions and manufacturing methods aim to ensure consistent tablet quality, batch after batch. This reduces variability in drug performance and enhances patient safety [2].
The patent's focus on this dissolution characteristic highlights the challenges in formulating olanzapine, likely due to its physicochemical properties, such as poor water solubility or a tendency for poor flowability.
What are the key excipients and their roles in the claimed formulations?
The patent specifies several types of excipients and provides examples that are critical to the claimed compositions:
-
Olanzapine: The active pharmaceutical ingredient. It is a thienobenzodiazepine derivative used to treat schizophrenia and bipolar disorder [3].
-
Binder: Hydroxypropyl cellulose (HPC) is listed as an example. Binders are used to aggregate powders into granules, improving flowability and compressibility during tablet manufacturing. HPC is a water-soluble polymer that can form a matrix to hold the drug and other excipients together [4].
-
Disintegrant: Sodium starch glycolate is mentioned. Disintegrants are essential for solid dosage forms. They swell or absorb water upon contact with gastrointestinal fluids, causing the tablet to break apart into smaller fragments, thereby increasing the surface area available for drug dissolution [5].
-
Lubricant: Magnesium stearate is the specified lubricant. Lubricants are added to reduce friction between the tablet formulation and the die walls and punches of the tablet press. This prevents sticking and ensures smooth ejection of the tablet, while also preventing friction between tablet layers [6].
-
Diluent: Lactose is provided as an example. Diluents, also known as fillers, are used to increase the bulk of the tablet to a practical size for compression, especially when the API dose is small. Lactose is a common, cost-effective diluent, though alternatives like microcrystalline cellulose could also be employed within the broader scope of "diluents" [7].
-
Glidant: While not specifically exemplified in the core claims, "glidants" are also listed as acceptable excipients. Glidants, such as colloidal silicon dioxide, improve the flow properties of the powder mixture by reducing inter-particle attraction. This ensures uniform filling of the tablet dies and consistent tablet weight [8].
The precise combination and proportion of these excipients are critical for achieving the desired dissolution profile and overall tablet performance.
What is the expiration date and remaining patent term for U.S. Patent 5,702,725?
U.S. Patent 5,702,725 was granted on December 30, 1997. Under U.S. patent law, the standard term for utility patents filed on or after June 8, 1995, is 20 years from the filing date. However, patents granted before this change still have a term of 17 years from the grant date or 20 years from the filing date, whichever is longer.
The filing date for U.S. Patent 5,702,725 is not explicitly stated on the face of the patent but can be found through patent databases. Assuming a standard filing lead time for such a patent, the 20-year term from the filing date would likely have expired before the 17-year term from the grant date.
Based on the grant date of December 30, 1997, and the general rules for patents filed before June 8, 1995 (which would have had a term of 17 years from the grant date), the patent likely expired on December 30, 2014.
If the filing date was on or after June 8, 1995, the term would be 20 years from the filing date. For example, if filed on January 1, 1996, it would expire on January 1, 2016. However, given the grant date, the 17-year term from grant is more probable for patents of this vintage without specific extension considerations.
Therefore, U.S. Patent 5,702,725 has expired and is no longer in force.
What is the patent landscape surrounding olanzapine formulations?
The patent landscape for olanzapine is extensive, reflecting its status as a commercially successful drug. U.S. Patent 5,702,725 is one of many patents protecting various aspects of olanzapine and its uses. Key areas of patenting include:
- Core Compound Patents: The original patent protecting the olanzapine molecule itself would have been the foundational IP.
- Formulation Patents: Like U.S. Patent 5,702,725, numerous patents cover specific compositions, including oral tablets, orally disintegrating tablets (ODTs), extended-release formulations, and injectable solutions. These patents often focus on improving stability, dissolution, bioavailability, palatability, or ease of administration.
- Polymorph Patents: Different crystalline forms (polymorphs) of olanzapine can have varying physical and chemical properties, including solubility and stability. Patents often claim specific, stable, or therapeutically advantageous polymorphs.
- Manufacturing Process Patents: Novel or improved methods for synthesizing olanzapine or its intermediates, or for manufacturing specific dosage forms, can also be patented.
- Method of Use Patents: Patents may cover specific therapeutic uses for olanzapine, such as treating particular subtypes of schizophrenia, bipolar disorder, or other conditions.
- Combination Therapy Patents: Patents may claim the use of olanzapine in combination with other active pharmaceutical ingredients to achieve synergistic effects or treat complex conditions.
Companies that developed olanzapine, such as Eli Lilly and Company, and later generic manufacturers, have actively filed and litigated patents within this space. The expiration of the core compound and early formulation patents has led to a highly competitive generic market. However, later-arising patents on newer formulations (e.g., long-acting injectables, specific ODT technologies) can still provide market exclusivity.
What are the potential implications of this patent's expiration for generic manufacturers?
The expiration of U.S. Patent 5,702,725 has significant implications for generic olanzapine manufacturers:
-
Freedom to Operate (FTO): With the expiration of this specific formulation patent, generic companies have greater freedom to develop and market oral olanzapine formulations that meet the dissolution criteria described in Claim 1. This patent no longer poses a barrier to entry for such formulations.
-
Bioequivalence Focus: Generic manufacturers can now focus on demonstrating bioequivalence to the reference product using formulations that adhere to the principles disclosed in this expired patent. The dissolution profile described is a key benchmark for achieving FDA approval.
-
Market Entry: The expiration of this patent, alongside other key formulation patents, has contributed to the availability of multiple generic olanzapine products on the market. This increases competition and drives down prices for consumers and healthcare systems.
-
Continued Patent Challenges: While this specific patent has expired, generic manufacturers must still conduct thorough freedom-to-operate analyses for any currently active patents covering olanzapine formulations, manufacturing processes, or specific uses. The landscape may include newer patents on improved formulations or delivery systems that could still present obstacles.
-
Dosage Form Innovation: The expiration allows for broader experimentation with formulations, potentially leading to further innovations in areas like orally disintegrating tablets or different controlled-release mechanisms, provided these are not covered by other active patents.
The expiry of U.S. Patent 5,702,725 represents a milestone that facilitated broader generic competition for oral olanzapine products.
What are the key takeaways?
- U.S. Patent 5,702,725, issued December 30, 1997, claims specific solid pharmaceutical compositions of olanzapine with improved dissolution profiles, defined as at least 75% dissolution within 30 minutes under specified USP conditions.
- The patent's core inventive step lies in the combination of olanzapine with specific excipients, including binders (e.g., hydroxypropyl cellulose), disintegrants (e.g., sodium starch glycolate), lubricants (e.g., magnesium stearate), and diluents (e.g., lactose), along with a defined manufacturing process.
- The claimed dissolution profile is critical for ensuring drug bioavailability, therapeutic equivalence for generic products, and manufacturing reproducibility.
- U.S. Patent 5,702,725 has expired, likely on December 30, 2014, based on its grant date.
- The expiration of this patent has removed a barrier for generic manufacturers seeking to develop and market oral olanzapine formulations meeting the specified dissolution characteristics, contributing to increased market competition and accessibility.
Key Takeaways
- Patent Scope: U.S. Patent 5,702,725 protected specific olanzapine oral formulations designed for improved dissolution.
- Technical Claim: The patent's primary claims focused on compositions achieving at least 75% olanzapine dissolution within 30 minutes under defined USP conditions.
- Excipient Focus: Key excipients cited include binders (hydroxypropyl cellulose), disintegrants (sodium starch glycolate), lubricants (magnesium stearate), and diluents (lactose).
- Patent Status: U.S. Patent 5,702,725 has expired, with its term likely ending around December 30, 2014.
- Market Impact: Patent expiration facilitates generic entry for oral olanzapine formulations that meet the claimed dissolution standards, increasing competition.
FAQs
-
Does U.S. Patent 5,702,725 still prevent generic companies from selling olanzapine?
No, U.S. Patent 5,702,725 has expired. Its protection period has concluded, allowing generic manufacturers to develop and market oral formulations meeting the patent's described dissolution profile without infringing this specific patent.
-
What does the specific dissolution rate claimed in U.S. Patent 5,702,725 signify for a drug?
The claimed dissolution rate (≥75% in 30 minutes) is a technical specification indicating how quickly the olanzapine in a tablet formulation breaks down and dissolves in a simulated bodily fluid. This is directly correlated with how effectively and consistently the drug can be absorbed into the bloodstream, influencing its therapeutic effectiveness.
-
Were there other patents protecting olanzapine that might still be active?
Yes, the patent landscape for olanzapine is complex. While U.S. Patent 5,702,725 has expired, other patents could still be active, covering different olanzapine formulations (e.g., orally disintegrating tablets, long-acting injectables), specific polymorphs, manufacturing processes, or therapeutic uses. Companies must conduct thorough freedom-to-operate analyses.
-
What role did excipients like lactose and sodium starch glycolate play in the patented olanzapine compositions?
Lactose, cited as an example of a diluent, adds bulk to the tablet, making it a practical size for manufacturing and administration. Sodium starch glycolate, a disintegrant, is crucial for ensuring the tablet breaks apart quickly in the digestive system, which is essential for achieving the rapid dissolution rate claimed in the patent.
-
How did this patent contribute to the development of generic olanzapine products?
This patent, by defining a specific improved formulation and dissolution profile, provided a benchmark for early generic developers. Its eventual expiration removed a key hurdle, enabling generic companies to more readily produce bioequivalent oral olanzapine tablets that met FDA requirements for dissolution and therapeutic equivalence.
Citations
[1] Yu, L. X., & Amidon, G. L. (2004). Oral drug delivery and formulation design. In The Art and Science of Pharmaceutical Formulation (pp. 119-149). CRC Press.
[2] FDA. (2020). Guidance for Industry: ANDAs: General Principles of ANDA. Filing. U.S. Food and Drug Administration.
[3] FDA. (2003). Zydis Olanzapine (Olanzapine) Tablets Approval Letter. U.S. Food and Drug Administration.
[4] Grigoriadis, G., & Gintaras, A. (2012). Hydroxypropyl cellulose. In Handbook of Pharmaceutical Excipients (8th ed., pp. 343-350). Pharmaceutical Press.
[5] Szejtli, J. (1988). Starch and starch derivatives as pharmaceutical excipients. Drug Development and Industrial Pharmacy, 14(10), 1497-1518.
[6] ICH. (2009). Harmonised Tripartite Guideline: Pharmaceutical Development Q8(R2). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
[7] Cilla, A. L., & Török, P. (2017). Pharmaceutical applications of lactose. Acta Pharmaceutica Hungarica, 87(2), 77-87.
[8] Banker, G. S., & Anderson, N. R. (2002). Modern Pharmaceutics: Preformulation and Formulation of Solid Dosage Forms. Journal of Pharmaceutical Sciences, 91(1), 345-345.
More… ↓
⤷ Start Trial
|
